SGLT2 inhibitors in heart failure with preserved ejection fraction

Area of Science:

• Cardiology
• Pharmacology
• Internal Medicine

Background:

• Heart failure (HF) is a significant global health burden.
• Heart failure with preserved ejection fraction (HFpEF), defined by left ventricular ejection fraction (LVEF) ≥50%, accounts for over half of HF cases and is increasing.
• Limited therapeutic options have historically been available for HFpEF, impacting hospitalization and mortality rates.

Purpose of the Study:

• To review current literature and clinical trials on sodium-glucose cotransporter 2 (SGLT2) inhibitors in HFpEF.
• To assess the efficacy of SGLT2 inhibitors in managing HFpEF.
• To explore the potential of SGLT2 inhibitors in reducing adverse outcomes in HFpEF patients.

Main Methods:

• Literature search of relevant clinical trials and studies.
• Analysis of data from randomized controlled trials investigating SGLT2 inhibitors in HFpEF.
• Synthesis of findings regarding the impact of SGLT2 inhibitors on HFpEF outcomes.

Main Results:

• Sodium-glucose cotransporter 2 (SGLT2) inhibitors have demonstrated significant benefits in HFpEF patients.
• These benefits include reductions in heart failure hospitalizations and cardiovascular mortality.
• Emerging evidence supports SGLT2 inhibitors as a key therapeutic class for HFpEF.

Conclusions:

• SGLT2 inhibitors represent a breakthrough in HFpEF treatment.
• Further research and clinical application are warranted to optimize their use.
• These agents offer a new avenue for improving prognosis in the growing HFpEF population.